Download presentation
Presentation is loading. Please wait.
Published byDaniel Newman Modified over 9 years ago
1
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Pharmacology in Nursing Antineoplastic Drugs Part 1: Cancer Overview and Cell Cycle– Specific Drugs
2
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Cancer Cellular transformation Uncontrolled and rapid cellular growth Invasion into surrounding tissue Metastasis to other tissues or organs
3
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Cancer (cont’d) Cancerous cells do not have: Growth control mechanisms Positive physiologic function Cancer cells either: Grow and invade adjacent tissues, or Break away from original tumor mass and travel by means of blood or lymphatic system to distant sites
4
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Cancer (cont’d) Primary lesion Original site of growth Metastasis Uncontrolled cell growth Secondary lesion, in a new and remote part of the body Neoplasm (“new tissue”) Mass of new cells; tumor Tumor Benign Malignant (cancer)
5
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
7
Cancer: Tissues of Origin Carcinomas Sarcomas Lymphomas and leukemias Also known as circulating tumors or hematologic malignancies
8
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Paraneoplastic Syndromes Various group of symptoms May be the first sign of malignancy Cachexia (most common) Fatigue, fever, weight loss Others
9
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Etiology of Cancer Age- and sex-related differences Genetic factors Ethnic factors Oncogenic viruses Occupational and environmental carcinogens Radiation Immunologic factors
10
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Cell Growth Cycle G 0 –resting phase G 1 –postmitotic phase S –DNA synthesis phase M –mitosis phase (cell reproduction)
11
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Chemotherapy Pharmacologic treatment of cancer Antineoplastic drugs Divided into two groups based on where in the cellular life cycle they work Cell cycle nonspecific (CCNS) Cell cycle specific (CCS) Some drugs have characteristics of both
12
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
13
Cancer Drugs: Antineoplastic Medications Cell cycle–nonspecific drugs Cytotoxic during a specific cell-cycle stage More effective against large, slowly growing tumors Alkylating drugs Cytotoxic antibiotics
14
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Cancer Drugs Antineoplastic Medications (cont’d) Cell cycle–specific drugs Drugs that are cytotoxic during a specific cell-cycle phase More effective against rapidly growing tumors Antimetabolites: folate, purine, and pyrimidine analogs Natural products: enzymes, vinca alkaloids, others
15
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Cancer Drugs: Antineoplastic Medications (cont’d) Miscellaneous cell cycle–specific drugs Miscellaneous antineoplastics (cell cycle specificity unclear) Hormonal agents Radioactive antineoplastics
16
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Chemotherapy (cont’d) Drugs have a narrow therapeutic index Combination of drugs is usually more effective than single-drug therapy Drug resistance Nearly all drugs cause adverse effects Dose-limiting adverse effects
17
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
19
Chemotherapy (cont'd) Harmful to all rapidly growing cells Harmful cancer cells Healthy, normal human cells Hair follicles Hair follicles GI tract cells GI tract cells Bone marrow cells Bone marrow cells
20
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Chemotherapy Terms Alopecia Emetic potential Myelosuppression Bone marrow suppression (BMS) Bone marrow depression (BMD) Nadir (low point) Extravasation
21
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Antimetabolites Folic acid antagonist methotrexate (MTX), others Purine antagonists fludarabine (F-AMP) mercaptopurine (6-MP) allopurionol, others Pyrimidine antagonists fluorouracil (5-FU) cytarabine (ARA-C), others
22
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Antimetabolites (cont’d) Folic acid antagonism Interferes with the use of folic acid As a result, DNA is not produced, and the cell dies
23
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Antimetabolites (cont’d) Purine antagonism Interrupts metabolic pathways of purine nucleotides Results in the interruption of the synthesis of DNA and RNA
24
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Antimetabolites (cont’d) Pyrimidine antagonism Interrupts metabolic pathways of pyrimidine bases Results in interruption of the synthesis of DNA and RNA
25
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Antimetabolites: Indications Used in combination with other drugs to treat various types of cancer, such as solid tumors and some hematologic cancers Acute and chronic lymphocytic leukemias Leukemias (several types) Colon, rectal, breast, stomach, lung, pancreatic cancers
26
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Antimetabolites: Indications (cont’d) Oral and topical forms may be used for low- dose maintenance and palliative cancer therapy Often used in combination chemotherapy regimens
27
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Antimetabolites: Adverse Effects Hair loss, nausea and vomiting, myelosuppression Many other severe adverse effects Leucovorin rescue may be done to reduce severe bone marrow suppression
28
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Mitotic Inhibitors Natural products obtained from the periwinkle plant Vinca alkaloids Semisynthetic drugs obtained from the mandrake (mayapple) plant Drugs obtained from the yew tree
29
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Mitotic Inhibitors (cont’d) Vinca alkaloids (periwinkle) vinblastine, vincristine, vinorelbine Epipodophyllotoxin derivatives (mandrake plant) etoposide, teniposide Taxanes doxetaxel (European yew tree: needles) paclitaxel (western yew tree: bark)
30
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Mitotic Inhibitors (cont’d) Work in various phases of the cell cycle All work shortly before, or during, mitosis Results in slowing of cell division All classified as CCS drugs
31
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Mitotic Inhibitors: Indications Often used in combination therapies Used to treat a variety of solid tumors and some hematologic malignancies Testicular, small-cell lung, breast, ovarian, non– small-cell lung cancers Kaposi’s sarcoma Acute leukemia
32
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Mitotic Inhibitors: Adverse Effects Hair loss, nausea and vomiting, myelosuppression Liver, kidney, lung toxicities Convulsions Extravasation Several specific antidotes can be used
33
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Topoisomerase-1 Inhibitors (Camptothecins) Derived from camptothecin, a substance taken from a Chinese shrub topotecan (Hycamtin) irinotecan (cpt-11, Camptosar)
34
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Topoisomerase-1 Inhibitors (Camptothecins) (cont’d) Cell cycle–specific drugs Inhibit proper DNA function in the S phase Prevent DNA religation
35
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Topoisomerase-1 Inhibitors (Camptothecins) (cont’d) Indications Ovarian and colorectal cancer Small-cell lung cancer Other tumors
36
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Topoisomerase-1 Inhibitors (Camptothecins) (cont’d) Adverse effects Bone marrow suppression (predictable, reversible, noncumulative, manageable) GI effects (nausea, vomiting, diarrhea) Irinotecan causes cholinergic diarrhea (delayed, occurring 2 to 10 days after dosage)
37
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Antineoplastic Enzymes Synthesized using cultures of bacteria and recombinant DNA technology As a result an enzyme is produced This enzyme is isolated and purified for clinical use asparaginase (Elspar): used to treat acute lymphocytic leukemia pegaspargase (Oncaspar)
38
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications Assess baseline blood counts before giving any antineoplastic drugs Follow specific administration guidelines for each antineoplastic drug
39
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Remember that all rapidly dividing cells (both normal and cancer cells) are affected Mucous membranes Hair follicles Bone marrow component Monitor for effects on these tissues or complications
40
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Monitor for complications GI mucous membranes: stomatitis, altered bowel function with high risk for poor appetite, nausea, vomiting, diarrhea, and inflammation and possible ulcerations of GI mucosa
41
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Monitor for complications Hair follicles: loss of hair (alopecia) Bone marrow components: dangerously low (life- threatening) blood cell counts Possible stimulation of CTZ (chemoreceptor trigger zone)
42
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Monitor for adverse effects specific to the type of antineoplastic drug given
43
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Implement measures to monitor for and prevent infection in patients with neutropenia or leukopenia
44
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Implement measures to monitor for and prevent bleeding in patients with thrombocytopenia and anemia
45
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Keep in mind that anemia may result in severe fatigue
46
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Monitor for stomatitis (oral inflammation and ulcerations) and implement measures to reduce the effects if it occurs
47
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Anticipate nausea and vomiting and implement measures to reduce these effects Antiemetics often work better if given 30 to 60 minutes before chemotherapy is started 30 to 60 minutes before chemotherapy is started
48
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) Women of childbearing age will need to use a nondrug form of contraception during therapy
49
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Nursing Implications (cont’d) In addition to physical measures, keep in mind the need for emotional support during this time for both the patient and family Monitor for therapeutic responses to antineoplastic therapies and the many possible adverse effects
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.